drugset / Trial / NCT05554965

Endoscopic Hemostatic and Sedative Treatment of Esophageal and Gastric Variceal Bleeding

NCT05554965

Phase 4 Unknown 60 enrolled Renmin Hospital of Wuhan University
Non-randomizedParallel-groupSingle-blindTreatment

Summary

Remazolam besylate was used for sedation during endoscopic hemostasis in patients with esophageal and gastric varices rupture and bleeding in liver cirrhosis. The onset time, recovery time and incidence of adverse reactions were observed.

Timeline

Start
2022-02-10
Primary completion
2022-10-30
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Propofol Small molecule 1.5 mg/kg
Subject Remimazolam Small molecule 0.1 mg/kg
Subject Remimazolam Small molecule 0.3 mg/kg

Indications

No indication recorded.